A study testing whether a new weekly shot from St. Jude Children's Research Hospital, tirzepatide, works for this condition.
- Who can join
- Adults 18+, have acute lymphoblastic leukemia, BMI 27+.
- What you take
- tirzepatide, given as part of the study at no cost to you. Some participants may receive a placebo (an inactive version) instead, decided at random.
- How long it lasts
- The full study runs about 2.6 years; your own time in it is usually shorter.
- What you get
- The study medication and study-related care at no cost. Compensation varies by study site; many cover travel and provide the study medication at no cost. The trial coordinator will explain what that site offers before you join.
What this study is for
Primary condition: Acute Lymphoblastic Leukemia. Also studied in: Obesity.
Full scientific study title: Resistance Exercise and Incretin Mimetic for Cardiometabolic Health in Survivors of ALL With Obesity.
Who can join
Adults 18+, have acute lymphoblastic leukemia, BMI 27+. A site coordinator confirms whether you qualify during a free screening visit. The exact medical requirements are below.
Full medical eligibility (for you and your doctor)verbatim from the registry
This is the exact wording from ClinicalTrials.gov, including clinical measures (lab values, imaging scores). Bring it to your doctor if any of it is unclear.
Key inclusion criteria
- >=5 years from diagnosis of acute lymphoblastic leukemia (ALL) treated with chemotherapy only
- >=2 years from completion of therapy
- Participant has a negative (urine or blood) pregnancy test (if female)
- Age >=18 years at the time of enrollment
- Participant has obesity (BMI > 30kg/m2) or overweight (BMI > 27kg/m2) with >=1 weight related co-morbidity (hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease)
Key exclusion criteria
- Participant has known diabetes or is found at baseline to have laboratory evidence of diabetes including HbA1c >= 6.5%
- Participant is using or has used weight management medication in the past 3 months or had recent significant weight loss > 5kg in the last 3 months Severe renal dysfunction (eGFR <30 mL/min/1.73 m²)
- Saxenda (liraglutide 3.0 mg)
- Xenical/Alli (orlistat)
- Meridia (sibutramine)
Where this study is enrolling
This trial has 1 sites across 1 state. Contact a site coordinator directly to start screening.
Tennessee1 site
- St. Jude Children's Research HospitalMemphis, Tennessee
Timeline
Started enrolling: 2026-04-23. Expected completion: 2028-11. Last updated on ClinicalTrials.gov: 2026-06-04.
Official source
We sync this data quarterly from ClinicalTrials.gov, the federal registry for clinical research. Before contacting a site, verify the trial is still recruiting on the official page:
Other GLP-1 clinical trials
Back to the full directory → or take the matching quiz if you want clinical trials filtered to your conditions and location.
